rs78378222
|
|
|
0.720 |
GeneticVariation |
BEFREE |
As rs78378222 changes the polyadenylation signal of TP53 leading to impaired 3'-end processing of TP53 mRNA, the SNP has strong plausibility for being directly functional contributing to the aetiological basis of glioma.
|
23571737 |
2013 |
rs1042522
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.
|
23096687 |
2012 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.
|
23096687 |
2012 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.
|
23096687 |
2012 |
rs55819519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
For this study, 164 cases of glioma were evaluated immunohistochemically for IDH1 mutations (R132H and R132S) using anti-IDH1 mAbs (HMab-1 and SMab-1).
|
22396072 |
2012 |
rs35850753
|
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study identifies multiple susceptibility loci for glioma.
|
26424050 |
2015 |
rs78378222
|
|
G |
0.720 |
GeneticVariation |
GWASCAT |
Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.
|
28346443 |
2017 |
rs55819519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
|
28427200 |
2017 |
rs55819519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
|
30760578 |
2019 |
rs1042522
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In conclusion, our meta-analysis, based on the combined data from published papers before May 2013, reveals no evidence for significant association between p53 Arg72Pro polymorphism and glioma risk.
|
24488625 |
2014 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In conclusion, our meta-analysis, based on the combined data from published papers before May 2013, reveals no evidence for significant association between p53 Arg72Pro polymorphism and glioma risk.
|
24488625 |
2014 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In conclusion, our meta-analysis, based on the combined data from published papers before May 2013, reveals no evidence for significant association between p53 Arg72Pro polymorphism and glioma risk.
|
24488625 |
2014 |
rs1042522
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In stratified analyses by ethnicity, source of controls, and glioma subtypes, the p53 codon 72 Arg/Pro polymorphism did not alter the risk for glioma in population-based, hospital-based, astrocytoma, and oligodendroglioma studies among Caucasian.
|
23860773 |
2013 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In stratified analyses by ethnicity, source of controls, and glioma subtypes, the p53 codon 72 Arg/Pro polymorphism did not alter the risk for glioma in population-based, hospital-based, astrocytoma, and oligodendroglioma studies among Caucasian.
|
23860773 |
2013 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In stratified analyses by ethnicity, source of controls, and glioma subtypes, the p53 codon 72 Arg/Pro polymorphism did not alter the risk for glioma in population-based, hospital-based, astrocytoma, and oligodendroglioma studies among Caucasian.
|
23860773 |
2013 |
rs1042522
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In this first assessment of the role of TP53 Arg72Pro polymorphism in a large series of Portuguese glioma tumors, no association was observed with glioma susceptibility or overall survival, except for patients submitted to adjuvant therapy.
|
18068527 |
2008 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In this first assessment of the role of TP53 Arg72Pro polymorphism in a large series of Portuguese glioma tumors, no association was observed with glioma susceptibility or overall survival, except for patients submitted to adjuvant therapy.
|
18068527 |
2008 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In this first assessment of the role of TP53 Arg72Pro polymorphism in a large series of Portuguese glioma tumors, no association was observed with glioma susceptibility or overall survival, except for patients submitted to adjuvant therapy.
|
18068527 |
2008 |
rs55819519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Interestingly, non-p.R132H mutations segregate in distinct histological and molecular subtypes of glioma.
|
20077503 |
2010 |
rs55819519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort.
|
23934175 |
2013 |
rs1800371
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data suggest that TP53 Pro47Ser and Arg72Pro SNPs are not involved either in susceptibility to developing gliomas or in patient survival, at least in the Brazilian population.
|
18393224 |
2008 |
rs1042522
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Our data suggest that TP53 Pro47Ser and Arg72Pro SNPs are not involved either in susceptibility to developing gliomas or in patient survival, at least in the Brazilian population.
|
18393224 |
2008 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our data suggest that TP53 Pro47Ser and Arg72Pro SNPs are not involved either in susceptibility to developing gliomas or in patient survival, at least in the Brazilian population.
|
18393224 |
2008 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our data suggest that TP53 Pro47Ser and Arg72Pro SNPs are not involved either in susceptibility to developing gliomas or in patient survival, at least in the Brazilian population.
|
18393224 |
2008 |
rs121912660
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our observations indicate that the R280T mutation of p53 regulates the proliferation of human glioma cells related to the GSK-3β/PTEN pathway.
|
22999923 |
2012 |